Inactive Instrument

EntreMed Inc Stock Nasdaq

US29382F2020

Pharmaceuticals

End-of-day quote Nasdaq
- ^USD	-

08-14	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-13	Casi Pharmaceuticals, Inc. Announces Management Changes	CI

CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Companyâ€™s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Companyâ€™s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.

Employees

Sector

Pharmaceuticals

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	3.29M 2.89M 2.73M 2.48M 4.65M 315M 4.68M 32.62M 12.63M 161M 12.35M 12.08M 518M	P/E 2024	-1.11x	P/E 2025	-0.33x
Enterprise Value	25.14M 22.06M 20.84M 18.99M 35.55M 2.41B 35.8M 249M 96.58M 1.23B 94.4M 92.36M 3.96B	EV / Sales 2024	1.75x	EV / Sales 2025	1.9x
Free-Float	53.46%	Yield 2024 *	-	Yield 2025	-

08-14	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-13	Casi Pharmaceuticals, Inc. Announces Management Changes	CI
06-02	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
05-15	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-15	CASI Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
04-20	CASI Pharmaceuticals, Inc. announced that it has received $20 million in funding from ETP Global III Fund LP	CI
04-20	CASI Pharmaceuticals, Inc. Announces Termination of Dr. Alexander A. Zukiwski, MD as Global Chief Medical Officer, Effective April 20, 2026	CI
03-03	CASI Pharmaceuticals, Inc. Announces CEO Changes	CI
03-03	Casi Pharmaceuticals, Inc. Announces Resignation of Director David Cory, Effective March 31, 2026	CI

08-14	CASI Pharmaceuticals Announces First Half 2026 Business and Financial Results	AQ
07-01	CASI Pharmaceuticals : Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Active and Chronic Active Antibody-mediated Rejection	PU

Manager	Title	Age	Since
David Cory CEO	Chief Executive Officer	62	21/07/2025
Kun Qian DFI	Director of Finance/CFO	44	16/05/2025
Chun Hua Wang COO	Chief Operating Officer	54	01/01/2017

Director	Title	Age	Since
Yue Wu BRD	Director/Board Member	62	01/04/2013
Zhen Bo Su BRD	Director/Board Member	50	21/03/2023
Thomas Folinsbee BRD	Director/Board Member	59	21/03/2023

EntreMed Inc Stock Nasdaq

Stocks

US29382F2020

Pharmaceuticals

Valuation: EntreMed Inc

Latest news: EntreMed Inc

Press Releases: EntreMed Inc

Managers and Directors: EntreMed Inc

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	+0.13%	+2.65%	+65.61%	+114.28%	1,053B
JOHNSON & JOHNSON	+0.20%	+0.46%	+52.60%	+69.24%	652B
ABBVIE INC.	-0.29%	+0.14%	+20.96%	+70.93%	468B
ROCHE HOLDING AG	-0.85%	-0.25%	+38.63%	+44.47%	351B
NOVARTIS AG	+0.71%	+3.26%	+22.46%	+30.30%	273B
ASTRAZENECA PLC	+1.23%	+1.00%	+11.97%	+13.63%	254B
AMGEN INC.	+2.11%	+7.51%	+52.89%	+55.37%	220B
GILEAD SCIENCES, INC.	+0.83%	+0.55%	+35.99%	+101.70%	186B
NOVO NORDISK A/S	0.00%	-9.43%	-31.91%	-60.56%	170B
Average	+0.40%	+0.30%	+29.91%	+48.82%	403.04B
Weighted average by Cap.	+0.26%	+1.00%	+41.03%	+68.05%

	2024	2025
Net sales	28.54M 25.04M 23.65M 21.55M 40.35M 2.74B 40.63M 283M 110M 1.4B 107M 105M 4.49B	20.71M 18.17M 17.17M 15.64M 29.28M 1.99B 29.49M 205M 79.56M 1.01B 77.77M 76.08M 3.26B
Net income	-39.26M -34.45M -32.54M -29.65M -55.5M -3.76B -55.9M -389M -151M -1.92B -147M -144M -6.18B	-48.06M -42.17M -39.83M -36.3M -67.94M -4.61B -68.43M -477M -185M -2.35B -180M -177M -7.56B
Net Debt	6.05M 5.31M 5.01M 4.57M 8.55M 580M 8.61M 60M 23.24M 296M 22.72M 22.22M 952M	21.85M 19.18M 18.11M 16.51M 30.9M 2.09B 31.12M 217M 83.95M 1.07B 82.05M 80.28M 3.44B